Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 (UW PIC 330)
Impact of Raltegravir (Isentress/MK-0518) - Containing Regimens on HIV-1 Infected CD4+ T-Cells During Acute and Early HIV-1 Infection: A Randomized, Controlled Study Comparing Standard Antiretroviral Therapy to Standard Therapy Plus Raltegravir
Sponsor: Merck Sharp & Dohme LLC
Terminated
Enrollment too slow.
Other terminated trials from Merck Sharp & Dohme LLC
- Melanoma · Phase PHASE2 · Feb 2026
- Advanced Solid Tumor · Phase PHASE2 · Jan 2026
- Lung Cancer Metastatic · Phase PHASE1/PHASE2 · Dec 2025
- Advanced and Metastatic Urothelial Cancer · Phase PHASE2 · Sep 2025
- Malignant Solid Tumor · Phase PHASE1 · Aug 2025
More terminations from Merck Sharp & Dohme LLC
Other Human Immunodeficiency Virus trials with similar outcome
This PHASE4 trial investigates Human Immunodeficiency Virus and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Feb 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of Washington
For direct contact, visit the study record on ClinicalTrials.gov .